In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Radich discusses at what point tyrosine kinase inhibitors can be stopped in the treatment of chronic myelogenous leukemia (CML).
A continuing education program is offered as a supplement to this webcast at the following location:
http://elc.imedex.com/ELC/Activity-Search.aspx?search=7204
© 2016 Imedex, LLC.